Richard D. Katz - 01 Feb 2022 Form 4 Insider Report for Allena Pharmaceuticals, Inc.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 01 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Feb 2022, 15:15:22 UTC
Source filing: View source filing
Reporting owner signature: /s/ Kevin Brennan, attorney-in-fact

Key filing fact

Richard D. Katz filed Form 4 for Allena Pharmaceuticals, Inc. on 02 Feb 2022.

Key facts

This page summarizes Richard D. Katz's Form 4 filing for Allena Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Feb 2022, 15:15.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALNAQ transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +255,000
Change %
Price: $0.000000
Shares after: 255,000
Date: 01 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 255,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units were granted pursuant to a retention plan approved by the board of directors of the Issuer.

Footnote F2

The restricted stock units will vest ratably in equal installments on July 15th and January 15th of each year over the three-year period immediately following February 1, 2022, and will accelerate in full upon the consummation of a change in control, in each case, subject to the Reporting Person's continued service through each applicable vesting date.